Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Authors

null

Anne C. Chiang

Yale Cancer Center, New Haven, CT

Anne C. Chiang , Charles M. Rudin , Alexander I. Spira , Robert M. Jotte , Shirish M. Gadgeel , Lowell L. Hart , William Larry Gluck , Stephen V. Liu , Ann M. Kapoun , Lu Xu , Dawn Hill , Lei Zhou , Jakob Dupont , David R. Spigel , Alain C. Mita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01859741

Citation

J Clin Oncol 34, 2016 (suppl; abstr 8564)

DOI

10.1200/JCO.2016.34.15_suppl.8564

Abstract #

8564

Poster Bd #

192

Abstract Disclosures